^
    28d
    CU06-1004 inhibits the progression of chronic colitis and colitis-associated colorectal cancer by suppressing inflammation. (PubMed, Front Pharmacol)
    Our findings suggest that CU06-1004 inhibits inflammation-induced tumorigenesis by modulating the inflammatory response in the colon. Consequently, CU06-1004 could represent a promising therapeutic candidate for the prevention of colorectal cancer through modulation of inflammation.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IL6 (Interleukin 6) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • TNFA (Tumor Necrosis Factor-Alpha) • CD177 (CD177 Molecule)
    |
    rivasterat (CU06)
    over1year
    The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P2, N=67, Completed, Curacle Co., Ltd. | Active, not recruiting --> Completed | Phase classification: P2a --> P2 | Trial completion date: Mar 2024 --> Jun 2023 | Trial primary completion date: Feb 2024 --> May 2023
    Trial completion • Phase classification • Trial completion date • Trial primary completion date
    |
    rivasterat (CU06)
    almost2years
    CU06-1004 alleviates oxidative stress and inflammation on folic acid-induced acute kidney injury in mice. (PubMed, J Pharmacol Sci)
    These findings suggest CU06-1004 as a potential therapeutic agent for folic acid-induced AKI.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • ICAM1 (Intercellular adhesion molecule 1) • KIM1 (Kidney injury molecule 1) • LCN2 (Lipocalin-2)
    |
    rivasterat (CU06)
    2years
    CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome. (PubMed, Front Pharmacol)
    Notably, the HDIL-2 and CU06-1004 combination therapy considerably reduced tumor growth in the B16F10 melanoma mouse model. Our data suggest that CU06-1004 acts as a potential anticancer drug candidate, not only by preventing HDIL-2-induced VLS but also by enhancing the anticancer effects of HDIL-2 immunotherapy.
    Journal
    |
    rivasterat (CU06)